Corvus Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is CRVS moving today?
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for CRVS.
CRVS insider activity
Corvus Pharmaceuticals Inc
No multi-insider buying cluster in the last 90 days
Net buying: $1.2M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-18 | MILLER RICHARD A MD | Insider | buy | $12.01 | 1,932 | 1,195,035 | $23K | SEC Form 4 |
| 2026-05-20 | 2026-05-18 | MILLER RICHARD A MD | Insider | buy | $12.05 | 5,000 | 1,193,103 | $60K | SEC Form 4 |
| 2026-01-30 | 2026-01-28 | Thompson Peter A. | Insider | buy | $2.12 | 15,000 | 210,000 | $32K | SEC Form 4 |
| 2026-01-30 | 2026-01-28 | Thompson Peter A. | Insider | buy | $1.64 | 15,000 | 195,000 | $25K | SEC Form 4 |
| 2026-01-30 | 2026-01-28 | Thompson Peter A. | Insider | buy | $2.49 | 15,000 | 180,000 | $37K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 14 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCRVS contract awards, year to date.
Public federal awards linked to this ticker.
CRVS lobbying filings, year to date.
Registered lobbying filings matched to Corvus Pharmaceuticals Inc.